tetano
Editor, Senior Moderator
[h=2]End of season influenza vaccine effectiveness in adults and children in the United Kingdom in 2017/18
[/h]
Aim To estimate the UK end-of-season 2017/18 adjusted vaccine effectiveness (aVE) and the seroprevalence in England of antibodies against influenza viruses cultured in eggs or tissue.
Methods This observational study employed the test-negative case?control approach to estimate aVE in primary care. The population-based seroprevalence survey used residual age-stratified samples.
Results Influenza viruses A(H3N2) (particularly subgroup 3C.2a2) and B (mainly B/Yamagata/16/88-lineage, similar to the quadrivalent vaccine B-virus component but mismatched to TIV) dominated. All-age aVE was 15% (95% confidence interval (CI): −6.3 to 32) against all influenza; −16.4% (95% CI: −59.3 to 14.9) against A(H3N2); 24.7% (95% CI: 1.1 to 42.7) against B and 66.3% (95% CI: 33.4 to 82.9) against A(H1N1)pdm09. For 2?17 year olds, LAIV4 aVE was 26.9% (95% CI: −32.6 to 59.7) against all influenza; −75.5% (95% CI: −289.6 to 21) against A(H3N2); 60.8% (95% CI: 8.2 to 83.3) against B and 90.3% (95% CI: 16.4 to 98.9) against A(H1N1)pdm09. For ≥ 18 year olds, TIV aVE against influenza B was 1.9% (95% CI: −63.6 to 41.2). The 2017 seroprevalence of antibody recognising tissue-grown A(H3N2) virus was significantly lower than that recognising egg-grown virus in all groups except 15?24 year olds.
Conclusions Overall aVE was low driven by no effectiveness against A(H3N2) possibly related to vaccine virus egg-adaption and a new A(H3N2) subgroup emergence. The TIV was not effective against influenza B. LAIV4 against influenza B and A(H1N1)pdm09 was effective.
full article
https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2019.24.31.1800488#html_fulltext
- Richard Pebody[SUP]1[/SUP], Abdelmajid Djennad[SUP]1[/SUP], Joanna Ellis[SUP]1[/SUP], Nick Andrews[SUP]1[/SUP], Diogo F P Marques[SUP]2[/SUP], Simon Cottrell[SUP]3[/SUP], Arlene J Reynolds[SUP]2[/SUP], Rory Gunson[SUP]4[/SUP], Monica Galiano[SUP]1[/SUP], Katja Hoschler[SUP]1[/SUP], Angie Lackenby[SUP]1[/SUP], Chris Robertson[SUP]5[/SUP], Mark O?Doherty[SUP]6[/SUP], Mary Sinnathamby[SUP]1[/SUP], Nikolaos Panagiotopoulos[SUP]1[/SUP], Ivelina Yonova[SUP]7,8[/SUP], Rebecca Webb[SUP]7[/SUP], Catherine Moore[SUP]3[/SUP], Matthew Donati[SUP]1[/SUP], Muhammad Sartaj[SUP]6[/SUP], Samantha J Shepherd[SUP]4[/SUP], Jim McMenamin[SUP]2[/SUP], Simon de Lusignan[SUP]7,8[/SUP], Maria Zambon[SUP]1[/SUP]
- Abstract
- Full-Text
- Figures & Tables
- References (33)
- Supplementary Material
- Metrics/Cited By
- Related Content
Aim To estimate the UK end-of-season 2017/18 adjusted vaccine effectiveness (aVE) and the seroprevalence in England of antibodies against influenza viruses cultured in eggs or tissue.
Methods This observational study employed the test-negative case?control approach to estimate aVE in primary care. The population-based seroprevalence survey used residual age-stratified samples.
Results Influenza viruses A(H3N2) (particularly subgroup 3C.2a2) and B (mainly B/Yamagata/16/88-lineage, similar to the quadrivalent vaccine B-virus component but mismatched to TIV) dominated. All-age aVE was 15% (95% confidence interval (CI): −6.3 to 32) against all influenza; −16.4% (95% CI: −59.3 to 14.9) against A(H3N2); 24.7% (95% CI: 1.1 to 42.7) against B and 66.3% (95% CI: 33.4 to 82.9) against A(H1N1)pdm09. For 2?17 year olds, LAIV4 aVE was 26.9% (95% CI: −32.6 to 59.7) against all influenza; −75.5% (95% CI: −289.6 to 21) against A(H3N2); 60.8% (95% CI: 8.2 to 83.3) against B and 90.3% (95% CI: 16.4 to 98.9) against A(H1N1)pdm09. For ≥ 18 year olds, TIV aVE against influenza B was 1.9% (95% CI: −63.6 to 41.2). The 2017 seroprevalence of antibody recognising tissue-grown A(H3N2) virus was significantly lower than that recognising egg-grown virus in all groups except 15?24 year olds.
Conclusions Overall aVE was low driven by no effectiveness against A(H3N2) possibly related to vaccine virus egg-adaption and a new A(H3N2) subgroup emergence. The TIV was not effective against influenza B. LAIV4 against influenza B and A(H1N1)pdm09 was effective.
full article
https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2019.24.31.1800488#html_fulltext